Dabigatran

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Dabigatran
Accession Number
DB14726
Description
Not Available
Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 471.521
Monoisotopic: 471.201887693
Chemical Formula
C25H25N7O3
Synonyms
  • Dabigatran
External IDs
  • BIBR 953 ZW
  • BIBR-953
  • BIBR-953-ZW

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of bleeding can be increased when Abciximab is combined with Dabigatran.
AceclofenacThe risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Dabigatran.
AcemetacinThe risk or severity of bleeding and hemorrhage can be increased when Acemetacin is combined with Dabigatran.
AcenocoumarolThe risk or severity of bleeding can be increased when Acenocoumarol is combined with Dabigatran.
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Dabigatran.
Albutrepenonacog alfaThe therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Dabigatran.
AlclofenacThe risk or severity of bleeding and hemorrhage can be increased when Alclofenac is combined with Dabigatran.
AldesleukinThe risk or severity of bleeding can be increased when Dabigatran is combined with Aldesleukin.
AlemtuzumabThe risk or severity of bleeding can be increased when Dabigatran is combined with Alemtuzumab.
AlteplaseThe risk or severity of bleeding can be increased when Alteplase is combined with Dabigatran.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
  • Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.

Products

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
I0VM4M70GC
CAS number
211914-51-1
InChI Key
YBSJFWOBGCMAKL-UHFFFAOYSA-N
InChI
InChI=1S/C25H25N7O3/c1-31-20-10-7-17(25(35)32(13-11-23(33)34)21-4-2-3-12-28-21)14-19(20)30-22(31)15-29-18-8-5-16(6-9-18)24(26)27/h2-10,12,14,29H,11,13,15H2,1H3,(H3,26,27)(H,33,34)
IUPAC Name
3-[1-(2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1H-1,3-benzodiazol-5-yl)-N-(pyridin-2-yl)formamido]propanoic acid
SMILES
CN1C(CNC2=CC=C(C=C2)C(N)=N)=NC2=C1C=CC(=C2)C(=O)N(CCC(O)=O)C1=NC=CC=C1

References

General References
Not Available
KEGG Drug
D09707
ChemSpider
187412
BindingDB
50112086
RxNav
1546356
ChEBI
70752
ChEMBL
CHEMBL48361
ZINC
ZINC000001910616
PDBe Ligand
4CC
Wikipedia
Dabigatran
PDB Entries
4jn2 / 4yhi / 4yhk / 4yhm / 4yho

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingPreventionAtrial Fibrillation (AF)1
4Active Not RecruitingTreatmentAtrial Fibrillation (AF) / Valve Heart Disease1
4CompletedBasic ScienceAcute Coronary Syndromes (ACS) / Atrial Fibrillation (AF)1
4CompletedBasic ScienceVenous Thromboembolism1
4CompletedPreventionAtrial Fibrillation (AF)1
4CompletedTreatmentAtrial Fibrillation (AF)2
4CompletedTreatmentCoronary Heart Disease (CHD)1
4Not Yet RecruitingTreatmentAtrial Fibrillation (AF) / Ischemic Heart Disease1
4RecruitingPreventionAtrial Fibrillation (AF)1
4RecruitingPreventionBleeding / Left Atrial Appendage Closure / Stroke / Thrombotic events / Transient Ischemic Attack (TIA)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0975 mg/mLALOGPS
logP2.37ALOGPS
logP0.077ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)3.18ChemAxon
pKa (Strongest Basic)12.52ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area150.22 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity143.26 m3·mol-1ChemAxon
Polarizability50.96 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on December 14, 2018 10:30 / Updated on July 10, 2020 21:43

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates